FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978729515> ?p ?o ?g. }

• W1978729515 endingPage "3468" @default.
• W1978729515 startingPage "3463" @default.
• W1978729515 abstract "Abstract BACKGROUND: Chemotherapy has not been reported to have a significant impact on survival for patients with metastatic melanoma. Bortezomib was shown to have additive/synergistic effects with several chemotherapeutic agents, including paclitaxel and platinum. A phase 1 trial of this 3‐drug combination reported that 6 of 28 patients treated with bortezomib followed by paclitaxel and carboplatin achieved a partial response (including 2 of 5 patients with metastatic melanoma). METHODS: A 2‐stage phase 2 clinical trial was conducted to assess the antitumor activity of this 3‐agent combination in patients with metastatic melanoma who had received at most 1 prior chemotherapy for metastatic disease. Treatment included bortezomib at a dose of 1.3 mg/m 2 intravenously on Days 1, 4, and 8; paclitaxel at a dose of 175 mg/m 2 ; and carboplatin at an area under the concentration (AUC) of 6 on Day 2 of a 21‐day cycle. The primary endpoint of this trial was tumor response rate (TRR). RESULTS: Seventeen eligible patients were enrolled. A median of 4 cycles were administered (range, 1‐7 cycles). Three patients discontinued treatment due to persistent grade 4 (based on National Cancer Institute Common Terminology Criteria for Adverse Events [version 3.0]) neutropenia with grade 3 leukopenia (2 patients) or grade 4 pulmonary embolism (1 patient). Grade ≥3 toxicities included neutropenia (71%), leukopenia (41%), thrombocytopenia (29%), and arthralgia (12%). Two partial responses were observed (TRR, 11.8%). Four patients had stable disease at >12 weeks. The median progression‐free survival was 3.2 months, and the median overall survival was 7.0 months. CONCLUSIONS: Due to insufficient clinical efficacy, this trial did not proceed to second‐stage accrual. The combination of paclitaxel, carboplatin, and bortezomib demonstrated limited clinical benefit and was associated with significant toxicity. Cancer 2010. © 2010 American Cancer Society." @default.
• W1978729515 created "2016-06-24" @default.
• W1978729515 creator A5001409992 @default.
• W1978729515 creator A5016095265 @default.
• W1978729515 creator A5022511085 @default.
• W1978729515 creator A5034081251 @default.
• W1978729515 creator A5035849162 @default.
• W1978729515 creator A5050428554 @default.
• W1978729515 creator A5071938679 @default.
• W1978729515 creator A5076793020 @default.
• W1978729515 creator A5082661564 @default.
• W1978729515 creator A5082719040 @default.
• W1978729515 date "2010-04-27" @default.
• W1978729515 modified "2023-10-16" @default.
• W1978729515 title "A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma" @default.
• W1978729515 cites W1879616740 @default.
• W1978729515 cites W1917632054 @default.
• W1978729515 cites W1967583401 @default.
• W1978729515 cites W1981342298 @default.
• W1978729515 cites W1981358533 @default.
• W1978729515 cites W1983202503 @default.
• W1978729515 cites W1991400488 @default.
• W1978729515 cites W2013660816 @default.
• W1978729515 cites W2026669555 @default.
• W1978729515 cites W2049306821 @default.
• W1978729515 cites W2052998982 @default.
• W1978729515 cites W2114847324 @default.
• W1978729515 cites W2118559527 @default.
• W1978729515 cites W2121001769 @default.
• W1978729515 cites W2132485651 @default.
• W1978729515 cites W2167395325 @default.
• W1978729515 cites W2264912071 @default.
• W1978729515 cites W2335735158 @default.
• W1978729515 cites W4211029100 @default.
• W1978729515 cites W4240858620 @default.
• W1978729515 doi "https://doi.org/10.1002/cncr.25191" @default.
• W1978729515 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3860743" @default.
• W1978729515 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20564112" @default.
• W1978729515 hasPublicationYear "2010" @default.
• W1978729515 type Work @default.
• W1978729515 sameAs 1978729515 @default.
• W1978729515 citedByCount "33" @default.
• W1978729515 countsByYear W19787295152012 @default.
• W1978729515 countsByYear W19787295152013 @default.
• W1978729515 countsByYear W19787295152014 @default.
• W1978729515 countsByYear W19787295152015 @default.
• W1978729515 countsByYear W19787295152016 @default.
• W1978729515 countsByYear W19787295152018 @default.
• W1978729515 countsByYear W19787295152019 @default.
• W1978729515 countsByYear W19787295152020 @default.
• W1978729515 countsByYear W19787295152021 @default.
• W1978729515 countsByYear W19787295152022 @default.
• W1978729515 countsByYear W19787295152023 @default.
• W1978729515 crossrefType "journal-article" @default.
• W1978729515 hasAuthorship W1978729515A5001409992 @default.
• W1978729515 hasAuthorship W1978729515A5016095265 @default.
• W1978729515 hasAuthorship W1978729515A5022511085 @default.
• W1978729515 hasAuthorship W1978729515A5034081251 @default.
• W1978729515 hasAuthorship W1978729515A5035849162 @default.
• W1978729515 hasAuthorship W1978729515A5050428554 @default.
• W1978729515 hasAuthorship W1978729515A5071938679 @default.
• W1978729515 hasAuthorship W1978729515A5076793020 @default.
• W1978729515 hasAuthorship W1978729515A5082661564 @default.
• W1978729515 hasAuthorship W1978729515A5082719040 @default.
• W1978729515 hasBestOaLocation W19787295151 @default.
• W1978729515 hasConcept C126322002 @default.
• W1978729515 hasConcept C141071460 @default.
• W1978729515 hasConcept C143998085 @default.
• W1978729515 hasConcept C197934379 @default.
• W1978729515 hasConcept C203092338 @default.
• W1978729515 hasConcept C2776364478 @default.
• W1978729515 hasConcept C2776694085 @default.
• W1978729515 hasConcept C2777063308 @default.
• W1978729515 hasConcept C2777292972 @default.
• W1978729515 hasConcept C2777478702 @default.
• W1978729515 hasConcept C2777793932 @default.
• W1978729515 hasConcept C2778239845 @default.
• W1978729515 hasConcept C2778850193 @default.
• W1978729515 hasConcept C2779984678 @default.
• W1978729515 hasConcept C2780873365 @default.
• W1978729515 hasConcept C2781451048 @default.
• W1978729515 hasConcept C31760486 @default.
• W1978729515 hasConcept C535046627 @default.
• W1978729515 hasConcept C71924100 @default.
• W1978729515 hasConcept C90924648 @default.
• W1978729515 hasConceptScore W1978729515C126322002 @default.
• W1978729515 hasConceptScore W1978729515C141071460 @default.
• W1978729515 hasConceptScore W1978729515C143998085 @default.
• W1978729515 hasConceptScore W1978729515C197934379 @default.
• W1978729515 hasConceptScore W1978729515C203092338 @default.
• W1978729515 hasConceptScore W1978729515C2776364478 @default.
• W1978729515 hasConceptScore W1978729515C2776694085 @default.
• W1978729515 hasConceptScore W1978729515C2777063308 @default.
• W1978729515 hasConceptScore W1978729515C2777292972 @default.
• W1978729515 hasConceptScore W1978729515C2777478702 @default.
• W1978729515 hasConceptScore W1978729515C2777793932 @default.
• W1978729515 hasConceptScore W1978729515C2778239845 @default.
• W1978729515 hasConceptScore W1978729515C2778850193 @default.

• next